Charm Therapeutics: CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug discovery using its proprietary DragonFold AI technology

PRESS RELEASE CHARM Therapeutics launches with a $50 million Series A financing to transform structure-based drug

Related Keywords

London ,City Of ,United Kingdom ,Muz Mansuri ,Sergey Bartunov ,Chris Bischoff ,Sarah Skerratt ,David Baker ,Nessan Bermingham ,Gary Glick ,Kostenloser Wertpapierhandel ,Alex Morgan ,Laksh Aithani ,Google Deepmind ,Garyd Glick ,Nihal Sinha ,Committee At Sanofi ,Vertex Pharmaceuticals ,Gilead Sciences ,Company Is ,Head Of The Institute For Protein Design ,Head Of Preclinical Sciences ,Pfizer ,University Of Washington ,Consilium Strategic Communications ,F Prime Capital ,General Catalyst ,Khosla Ventures ,Executive Chair ,Chief Executive Officer ,Board Member ,Protein Design ,Wiley Prize ,Scorpion Therapeutics ,Odyssey Therapeutics ,Venture Partner ,Executive Committee ,Orchard Therapeutics ,Rishi Gupta ,Senior Vice President ,Drug Discovery ,Preclinical Sciences ,Managing Director ,Intellia Therapeutics ,Chief Executive ,Charm ,Herapeutics ,Harm ,Aunches ,Billion ,Series ,Financing ,Ransform ,Structure ,Ased ,Drug ,Discovery ,Sing ,Roprietary ,Ragonfold ,Technology ,